Paclitaxel administered over 3 h followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: A clinical phase i study

Oncology (Switzerland)

Volumn 54, Issue 2, 1997, Pages 89-95

  Schilling, Tassilo ^a   Heinrich, Bernhard ^a   Kau, Reinhardt ^b   Herzog, Michael ^b   Quasthoff, Stefan ^b   Diergarten, Klaus ^c   Rastetter, Johann ^a   Hanauske, Axel R ^a  

^a Department of Pediatrics   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cisplatin; Head neck cancer; Paclitaxel; Phase I

Indexed keywords

CIMETIDINE; CISPLATIN; CLEMASTINE; DEXAMETHASONE; ONDANSETRON; PACLITAXEL;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HEMATOPOIESIS; HUMANS; HYPOTENSION, ORTHOSTATIC; INFUSIONS, INTRAVENOUS; LEUKOPENIA; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NERVOUS SYSTEM DISEASES; TREATMENT OUTCOME;

EID: 0031058673     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227669     Document Type: Article

References (32)

1. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995, CA 1995;1:8-30.
2. Kotwall C, Sako K, Razack MS, Rao U, Ba-kamjian V, Shedd DP: Metastatic patterns in squamous cell cancer of the head and neck, Am JSurg 1987;154:439-442.
3. Clavel M, Vermorkcn JB, Cognetti F, Cappe-laere P, de Mulder PH, Schornagel JH, Tucni EA, Verweij J, Wildtcrs J, Clerico M, Dalesio O, Kirkpatrick A, Snow GB: Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck, A phase III study of the HORTC Head and Neck Cancer Cooperative Group, Ann Oncol 1994:5:521-526.
4. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, Jirillo A, Tornio L, Fila G, Fede A, Endrizzi L, Bari M, Sampo-gnaro E, Balli M, Gava A, Pappagallo GL, Fiorentino MV: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo, J Natl Cancer Inst 1994;86:265-272.
5. Hill BT, Price LA: Lack of survival advantage in patients with advanced squamous cell carcinomas of the oral cavity receiving neoadjuvant chemotherapy prior to local therapy, despite achieving an initial high clinical complete remission rate, Am J Clin Oncol 1994;17:1-5.
6. Jacobs C, Lyman G, Velez Garcia E, Sridhar KS, Knight W, Höchster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, Chamg N, Dalton T, Burroughs J, Rozenczeig M: A phase II randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck, J Clin Oncol 1992; 10: 257-263.
7. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forasticrc AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, Comblath DR, Hendricks C, Donehower RC: Sequences of Taxol and cisplatin: A phase I and pharmacologic study, J Clin Oncol 1991:9:1692-1703.
8. Calimcl G, Vermorken JB, Clavel M, De Mulder P, Judson I, Scssa C, Piccart M, Bruntsch U, Verweij J, Wanders I, Franklin H, Kaye SB: A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck: EORTC Early Clinical Trials Group, Ann Oncol 1994: 5:543-547.
9. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, Franklin H, Lc Bail N, Clavel M, Kaye SB: Docetaxel (Taxotere-): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck, Ann Oncol 1994;5:533-537.
10. Cascinu S, Fedeli A, Luzi Fedeli S, Catalano G: Cisplatin, 5-lluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer, Br J Cancer 1994;69:392-393.
11. de Mulder PH, Cappelaere P, Cognetti F, Verweij J, Sehornagel JH, Vermorken JB, Kirkpatrick A, Lefebvre JL: A phase II study of piraru-bicin in patients with advanced recurrent head and neck squamous cell carcinoma, Cancer Chcmothcr Pharmacol 1994;33:438-440.
12. Parness J, Horwitz SB: Taxol binds to polymerized tubulins in vitro, J Biol Chem 1981:91: 479-487.
13. Forastiere AA: Paclitaxel (Taxol) for the treatment of head and neck cancer, Semin Oncol 1994:21:49-52.
14. Thornton D, Singh K, Putz B, Gams R, Schuller D, Smith R: A phase II trial of Taxol in squamous cell carcinoma of the head and neck, Proc Am Soc Clin Oncol 1994; 13:288.
15. Rowinsky EK, Chaudhrv V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubej-ko BG, Cornblath DR, Donehowcr RC: Phase 1 and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting, J Clin Oncol 1993; 11:2010-2020.
16. Jekunen AP, Christen RD, Shalinsky DR, Howell SB: Synergistic interaction between cisplatin and Taxol in human ovarian carcinoma cells in vitro, Br J Cancer 1994:69:299-306.
17. Vanhocfcr U, Harstrick A, Wilke H, Schleu-cher N, Walles H, Schroder J, Seeber S: Schc-dule-dcpendcnt antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro, Eur J Cancer 1995;31 A: 92-97.
18. Hansen HH, Eisenhauer EA, Hansen M, Neijt JP, Piccart MJ, Sessa C, Thigpen JT: New cytostatic drugs in ovarian cancer, Ann Oncol 1993;4(suppl 4):63-70.
19. Chou TC, Motzcr RJ, Tong Y, Bosl GJ: Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design (see comments), J Natl Cancer Inst 1994:86: 1517-1524.
20. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR: Peripheral neuropathy from Taxol and cisplatin combination chemotherapy: Clinical and electrophysio-logical studies, Ann Neurol 1994;35:304-311.
21. Bostock H, Sharief MK, Reid G, Murray NM: Axonal ion channel dysfunction in amyotrophic lateral sclerosis, Brain 1995:118:217-225.
22. Horn S, Quasthol TS, Grafe P, et al: Abnormal axonal inward rectification in diabetic neuropathy, J Neurol, in press.
23. Quasthol T S, Grosskreutz J, KUhn M, et al: Taxol-cisplatin neuropathy caused by membrane leak and axonal depolarisation: An in vivo and in vitro study, J Neurol 1995; 242(suppl 2): 145.
24. Klastersky J, Sculier JP: Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer, Semin Oncol 1994: 21:39-43.
25. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC: Clinical toxicities with paclitaxel (Taxol'*), Semin Oncol 1993; 20(suppl 3):1-15.
26. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E: Phase I clinical and pharmacokinetic study of Taxol, Cancer Res 1987;47:2486-2493.
27. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP: Phase I trial of Taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma, J Clin Oncol 1987:5:1232-1239.
28. Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Spriggs D: A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor, Semin Oncol 1994:21:9-14.
29. Belli L, Le Chevalier T, Gottfried M, Adams D, RufTie P, Le Cesnc A, Tete L, Pellae-Cossct B: Phase I-II trial of paclitaxel (Taxol*) and cisplatin in previously untreated advanced nonsmall cell lung cancer (NSCLC), Proc Am Soc Clin Oncol 1995:14:350.
30. Giaccone G, Splinter TAW, Postmus P, van Meerbeeck J, Debruyne C, Sahmoud T: Tenip-osidc-cisplatin vs, paclitaxel-cisplatin in advanced non-small cell lung cancer (NSCLC): Results of a randomized phase II study of the EORTC-LCCG, Proc Am Soc Clin Oncol 1995:14:356.
31. Frazcin A, Wasserheit C, Hochster H, Oratz R, Wemz J, Chachoua A, Meyers M, Sorich J, Downey A, Blum R, Speyer J: High rate of peripheral neuropathy may limit paclitaxel (T) and cisplatin (DDP) combination in women with advanced breast cancer (BC), Proc Am Soc Clin Oncol 1995;14:111.
32. Hitt R, Hornedo J, Colmoer R, Mcndiola C, Brandariz A, Sevilla E, Alvarez-Vicent J, Cortes-Funes H: Phase I/II study of escalating doses ofTaxoI + cisplatin with G-CSF (Filgas-trim) as first-line therapy for head and neck carcinomas, Preliminary results, Proc Am Soc Clin Oncol 1995:14:300.